Abstract:Background Immune checkpoint inhibitor (ICI) therapy has revolutionized the treatment of many cancers. However, the limited population that benefits from ICI therapy makes it necessary to screen predictive biomarkers for stratifying patients. Currently, many biomarkers, such as tumor mutational burden (TMB), have been used in the clinic as indicative biomarkers. However, some high-TMB patients with mutations in genes that are closely related to immunotherapeutic resistance are not sensitive to ICI therapy. Thus, there is a need to move beyond TMB and identify specific genetic determinants of the response to ICI therapy. In this study, we established a comprehensive mutation-based gene set across different tumor types to predict the efficacy of ICI therapy. Methods We constructed and validated a mutational signature to predict the prognosis of patients treated with ICI therapy. Then, the underlying immune response landscapes of different subtypes were investigated with multidimensional data. Results This study included genomic and clinical data for 12,647 patients. An eleven-gene mutation-based gene set was generated to divide patients into a high-risk group and a low-risk group in a training cohort (1572 patients with 9 types of cancers who were treated with ICI therapy). Validation was performed in a validation cohort (932 patients with 5 types of cancers who were treated with ICI therapy). Mutations in these 11 genes were associated with a better response to ICI therapy. In addition, the mutation-based gene set was demonstrated to be an independent prognostic factor after ICI therapy. We further explored the role of the immune context in determining the benefits of immunotherapy in 10,143 patients with 33 types of cancers and found distinct immune landscapes for the high- and low-risk groups. Conclusions The mutation-based gene set developed in this study can be used to reliably predict survival benefit across cancers in patients receiving ICI therapy. The close interplay between the extrinsic and intrinsic immune landscapes in the identified patient subgroups and the subgroups' differing responses to ICI therapy could guide immunotherapy treatment decisions for cancer patients.

MA05.03 Utilization of Genomic Mutation Signature to Predict the Immunotherapy Response in Non-small Cell Lung Cancer

Delta Radiomics Model for the Prediction of Progression-Free Survival Time in Advanced Non-Small-cell Lung Cancer Patients after Immunotherapy.

Identification of Immune-Related Gene Signature for Non-Small Cell Lung Cancer Patients with Immune Checkpoint Inhibitors

Identification and Validation of a Genomic Mutation Signature As a Predictor for Immunotherapy in NSCLC.

Identification of Nomogram Associated with Durable Clinical Benefit Gene for Advanced Non-Small Cell Lung Cancer with Sensitivity to Responsive to Immunotherapy

A 20-gene mutation signature predicts the efficacy of immune checkpoint inhibitor therapy in advanced non-small cell lung cancer patients

Development and Validation of a Genomic Mutation Signature to Predict Response to PD-1 Inhibitors in Non-Squamous NSCLC: a Multicohort Study

A Predictive Model for Evaluating Efficacy of Immunotherapy in Non-small-cell Lung Cancer Patients

The Immune Response-Related Mutational Signatures and Driver Genes in Non-Small-cell Lung Cancer

Tumor Microenvironment Assessment-Based Signatures for Predicting Response to Immunotherapy in Non-Small Cell Lung Cancer

Molecular characterization of clinical responses to PD-1/PD-L1 inhibitors in non-small cell lung cancer: Predictive value of multidimensional immunomarker detection for the efficacy of PD-1 inhibitors in Chinese patients.

Identification of Immune-Related Gene Signature Model for Predicting Lung Cancer Survival and Response to Immunotherapy

A New Immune Signature for Survival Prediction and Immune Checkpoint Molecules in Non-Small Cell Lung Cancer

Integrated genomic analysis identifies a genetic mutation model predicting response to immune checkpoint inhibitors in melanoma

Survival prediction model for non-small cell lung cancer based on somatic mutations.

Comprehensive Genomic Profiling Identifies Novel Genetic Predictors of Response to Anti-Pd-(l)1 Therapies in NSCLC.

A prospective multi-cohort study identifies and validates a 5-gene peripheral blood signature predictive of immunotherapy response in non-small cell lung cancer

CT radiomics-based model for predicting TMB and immunotherapy response in non-small cell lung cancer

A Mutation-Based Gene Set Predicts Survival Benefit after Immunotherapy Across Multiple Cancers and Reveals the Immune Response Landscape

Co-occurring genomic alterations and immunotherapy efficacy in NSCLC

Insights into treatment-specific prognostic somatic mutations in NSCLC from the AACR NSCLC GENIE BPC cohort analysis